NCT02903914 · OUTCOME

AUC0-tau of INCB001158 Following Multiple Escalating Doses for Part 1A

Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors · Source last updated 2025-08-05

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: GEOMETRIC_MEAN
Unit: hours x ng/mL
Interval / dispersion: Geometric Coefficient of Variation
Time frame: Cycle 1 Day 15: predose; 0.5, 1, 2, 4, 6, 8, and 12 hours post-dose

What was measured

AUC0-tau was defined as the area under the concentration-time curve from dosing (time 0) of INCB001158 to the end of the dosing period.

Analysis population: PK Population. Only participants with available data were analyzed.

Groups in this outcome

Part 1A: INCB001158 50 mg

INCB001158 was administered orally at 50 milligrams (mg) twice daily (BID) in participants with advanced/metastatic solid tumors.

Part 1A: INCB001158 75 mg

INCB001158 was administered orally at 75 mg BID in participants with advanced/metastatic solid tumors.

Part 1A: INCB001158 100 mg

INCB001158 was administered orally at 100 mg BID in participants with advanced/metastatic solid tumors.

Part 1A: INCB001158 150 mg

INCB001158 was administered orally at 150 mg BID in participants with advanced/metastatic solid tumors.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Part 1A: INCB001158 50 mg	6
Part 1A: INCB001158 75 mg	4
Part 1A: INCB001158 100 mg	4
Part 1A: INCB001158 150 mg	6

Reported measurements

Source class 1

Values in hours x ng/mL · Interval/dispersion: Geometric Coefficient of Variation
Group	Value	Spread	Lower	Upper	Comment
Part 1A: INCB001158 50 mg	8250	0.27	Not reported	Not reported	Not reported
Part 1A: INCB001158 75 mg	16600	0.39	Not reported	Not reported	Not reported
Part 1A: INCB001158 100 mg	18300	0.34	Not reported	Not reported	Not reported
Part 1A: INCB001158 150 mg	29700	0.31	Not reported	Not reported	Not reported

Source statistical analyses

Group order, estimate direction, methods and comments are retained. No treatment ranking is inferred.

group Ids
OG000
OG001
OG002
OG003
non Inferiority Type
OTHER
p Value
0.1705
statistical Comment
1-factor ANOVA of log-transformed, dose-normalized data (factor = dose)
statistical Method
ANOVA
ci Lower Limit
0.863
ci Num Sides
TWO_SIDED
ci Pct Value
90
ci Upper Limit
1.359
group Ids
OG002
OG003
non Inferiority Type
OTHER
param Type
pairwise GMR
param Value
1.083
ci Lower Limit
0.719
ci Num Sides
TWO_SIDED
ci Pct Value
90
ci Upper Limit
1.132
group Ids
OG000
OG002
non Inferiority Type
OTHER
param Type
pairwise GMR
param Value
0.902
ci Lower Limit
0.945
ci Num Sides
TWO_SIDED
ci Pct Value
90
ci Upper Limit
1.554
group Ids
OG001
OG002
non Inferiority Type
OTHER
param Type
pairwise GMR
param Value
1.212

Complete source fields

analyses

group Ids
OG000
OG001
OG002
OG003
non Inferiority Type
OTHER
p Value
0.1705
statistical Comment
1-factor ANOVA of log-transformed, dose-normalized data (factor = dose)
statistical Method
ANOVA
ci Lower Limit
0.863
ci Num Sides
TWO_SIDED
ci Pct Value
90
ci Upper Limit
1.359
group Ids
OG002
OG003
non Inferiority Type
OTHER
param Type
pairwise GMR
param Value
1.083
ci Lower Limit
0.719
ci Num Sides
TWO_SIDED
ci Pct Value
90
ci Upper Limit
1.132
group Ids
OG000
OG002
non Inferiority Type
OTHER
param Type
pairwise GMR
param Value
0.902
ci Lower Limit
0.945
ci Num Sides
TWO_SIDED
ci Pct Value
90
ci Upper Limit
1.554
group Ids
OG001
OG002
non Inferiority Type
OTHER
param Type
pairwise GMR
param Value
1.212

classes

categories
measurements
group Id
OG000
spread
0.27
value
8250
group Id
OG001
spread
0.39
value
16600
group Id
OG002
spread
0.34
value
18300
group Id
OG003
spread
0.31
value
29700

denoms

counts
group Id
OG000
value
6
group Id
OG001
value
4
group Id
OG002
value
4
group Id
OG003
value
6
units
Participants

description

AUC0-tau was defined as the area under the concentration-time curve from dosing (time 0) of INCB001158 to the end of the dosing period.

dispersion Type

Geometric Coefficient of Variation

groups

description
INCB001158 was administered orally at 50 milligrams (mg) twice daily (BID) in participants with advanced/metastatic solid tumors.
id
OG000
title
Part 1A: INCB001158 50 mg
description
INCB001158 was administered orally at 75 mg BID in participants with advanced/metastatic solid tumors.
id
OG001
title
Part 1A: INCB001158 75 mg
description
INCB001158 was administered orally at 100 mg BID in participants with advanced/metastatic solid tumors.
id
OG002
title
Part 1A: INCB001158 100 mg
description
INCB001158 was administered orally at 150 mg BID in participants with advanced/metastatic solid tumors.
id
OG003
title
Part 1A: INCB001158 150 mg

param Type

GEOMETRIC_MEAN

population Description

PK Population. Only participants with available data were analyzed.

reporting Status

POSTED

time Frame

Cycle 1 Day 15: predose; 0.5, 1, 2, 4, 6, 8, and 12 hours post-dose

title

AUC0-tau of INCB001158 Following Multiple Escalating Doses for Part 1A

type

SECONDARY

unit Of Measure

hours x ng/mL

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice